EXCLUSIVE: India orders Sun Pharma to halt eye-care drug production at plant after quality lapses Reuters
EXCLUSIVE: India orders Sun Pharma to halt eye-care drug production at plant after quality lapses - Reuters
In short
Indian authorities have ordered Sun Pharma to halt the production of eye-care drugs at a manufacturing plant. The enforcement action follows the discovery of quality lapses at the impacted site during official oversight procedures. The halt directly restricts the company's output until manufacturing protocols are aligned with necessary domestic standards.
Key points
- Sun Pharma faces regulatory disruption to its manufacturing operations due to mandatory h…: Sun Pharma faces regulatory disruption to its manufacturing operations due to mandatory halts.
- Quality control lapses at the facility led directly to government intervention on eye-car…: Quality control lapses at the facility led directly to government intervention on eye-care drugs.
- The company must address the flagged production standards before eye-care manufacturing c…: The company must address the flagged production standards before eye-care manufacturing can resume safely.